Selected publications
-
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Cancer Discovery.
2019
Academic Article
GET IT
Times cited: 13 - Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer. Clinical Cancer Research. 2019 Academic Article GET IT
-
Genetic predictors of response to systemic therapy in esophagogastric cancer.
Cancer Discovery.
2018
Academic Article
GET IT
Times cited: 57 -
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Gastric Cancer.
2018
Academic Article
GET IT
Times cited: 2